Pegunigalsidase alfa

ELFABRIO is indicated for the treatment of adults with confirmed Fabry disease.

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear.

Drug facts

Used for: ELFABRIO is indicated for the treatment of adults with confirmed Fabry disease.

What it is used for

ELFABRIO is indicated for the treatment of adults with confirmed Fabry disease. ELFABRIO is a hydrolytic lysosomal neutral glycosphingolipid-specific enzyme indicated for the treatment of adults with confirmed Fabry disease.

Cite this page

NLM: sofidex [Internet]. Daloreum; c2026. Pegunigalsidase alfa; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/pegunigalsidase-alfa
APA 7th: sofidex. (2026, August 3). Pegunigalsidase alfa. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/pegunigalsidase-alfa
AMA 11th: Pegunigalsidase alfa. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/pegunigalsidase-alfa

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.